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ScienceDirectThe ability of antibiotics to cure bacterial infections is at a serious
risk due to the emergence and worldwide spread of superbugs. A
lack of innovation and investment for almost 50 years has led to
significant efforts currently being devoted to find alternative and
innovative therapies to face this challenge. This short review
highlights some of the recent efforts to develop synthetic small
molecules with anti-infective activity. This article is focused on
those compounds that, when co-administered with an antibiotic,
enhance the antimicrobial action of the drug, as well as
compounds that target unexplored objectives for bacterial
survival. Selected examples are provided.
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Introduction
Antibiotics are probably the drugs that have transformed
modern medicine the most. These drugs have managed to:
(i) cure diseases that were fatal in the past, (ii) contribute
greatly to increased life expectancy, and (iii) manage com-
mon infectious complications in vulnerable patients under-
going treatment. In all of these cases, the ability to treat
secondary infections is crucial for patient recovery. Unfortu-
nately, the ability of these drugs to cure infections caused by
bacteria is now at serious risk due to the emergence and
worldwide spread of superbugs (multi-resistant) [1]. Of
particular concern is the increasing incidence in health-
care-associated systems, since in these cases the weak
immune systems of patients facilitate the pathogenicity of
bacteria. Resistance to antibiotics is reaching such dangerouswww.sciencedirect.com levels that the World Health Organization (WHO) estimates
that by 2050 around 10 million people could die every year as
a result of this problem, and deaths from antibiotic resistance
will exceed those caused by cancer.
Although bacteria will always be resistant due to their
adaptability and intrinsic evolutionary character to develop
highly efficient resistance mechanisms to escape the action
of antibiotics, we must have solutions to keep them under
control [2]. To this end, given the gap in investment in
R&D by the big pharmaceutical companies since the 1960s
and the small number of innovative approaches employed,
which were mainly focused on improving existing drugs,
anti-infective discovery strategies are currently focused on
two approaches: (i) the development of antibiotic adjuvants
for combined therapy with the existing antibiotics in clini-
cal use; and (ii) the discovery of small molecules with new
mechanisms of action that can disable unexplored objec-
tives for bacterial survival [3]. This short review high-
lights some recently described synthetic small molecules
with anti-bacterial activity in the context of the two strate-
gies outlined above.
Antibiotic adjuvants  b-lactamase inhibitors
Antibiotic adjuvants, also named resistance breakers
or antibiotic potentiators, are compounds that do not
inhibit bacterial growth in their own right but when co-
administered with the antibiotic they enhance the anti-
microbial action of the latter [4–6,7,8–10,11]. Adjuvants
breathe new life into antibiotics that have saved millions
of lives for years but are now inefficient against superb-
ugs. The most remarkable antibiotic adjuvants are those
that block the main bacterial resistance mechanism to
b-lactam antibiotics, that is, enzymatic inactivation of the
drug by hydrolysis of the b-lactam core in an acylation–
deacylation-based process catalyzed by b-lactamases
enzymes. Among the four known types of b-lactamases
(A–D), the most worrisome ones are the class D
b-lactamases (oxicillinases, OXA) because they can inac-
tivate the entire spectrum of b-lactam antibiotics, peni-
cillins, cephalosporins, and even carbapenems, which are
the antibiotics of last resort [12]. These b-lactamases are
widespread among the multi-resistant healthcare-associ-
ated infections caused by the Gram-negative ESKAPE
pathogens, such as Pseudomonas aeruginosa, Acinetobacter
baumannii and Enterobacteriaceae, which were designated
in 2017 by the WHO as the top priority pathogens for the
development of novel anti-infective therapies [13]. The
b-lactamase inhibitors in clinical use, namely clavulanic
acid, sulbactam, and tazobactam, are ineffective againstCurrent Opinion in Pharmacology 2019, 48:17–23
18 Anti-infectivesclass D b-lactamases and much effort has, therefore, been
devoted to the development of more effective chemical
entities, with some examples already in clinical studies.
These compounds fundamentally fall into two categories:
(1) diazabicyclooctanes and (2) boronic acids (Figure 1).
Diazabicyclooctanes (DBOs)
These are bicyclic compounds that undergo ring opening
of their urea core by the catalytic serine to afford a stable
carbamoyl adduct. The most representative example is
avibactam, which was approved in 2014 by the FDA in
combination with ceftazidime and is actually in clinical
studies in combination with other antibiotics (Figure 1a)
[14,15]. Avibactam has a unique mechanism of inhibition
among the b-lactamase enzymes since it proved to be a
covalent and slowly reversible inhibitor [16–18]. It has
also been shown that avibactam targets penicillin-binding








Most relevant b-lactamase inhibitors. (a) Diazabicyclooctanes. (b) Boronic a
Current Opinion in Pharmacology 2019, 48:17–23 compound is its variable inhibitory capacity against car-
bapenem-hydrolyzing class D b-lactamases, in particular
OXA-24/40 and OXA-23, which represent the most prev-
alent and dangerous examples in the WHO top priority
pathogens. The latter effect is due to the uncommon
geometry of the active site, which has a tunnel-like
entrance formed by Tyr/Phe and Met residues that act
as a hydrophobic filter to allow the entrance of only
certain substrates. In an effort to extend the avibactam
spectrum activity, the DBO scaffold has been modified
either by introducing other functional groups in position
C2 or by functionalizing the cyclohexane core in positions
C3 and C4. For example, Durand-Réville et al. [19]
reported that the introduction of a double bond between
positions C3 and C4 of avibactam and the inclusion of a
methyl group in C3, that is, compound ETX2514, enables
effective inhibition of the most dangerous OXA enzymes
in A. baumannii, OXA-24/40 and OXA-23. In combinationWCK 4234 (2), R = CN
Relebactam  (3), R = 
WCK 5153 (4), R = 
 Zidebactam ( 5), R  =
OP0595 (6), R =
11 Z = N, X = H
12 Z = CH, X = Cl
9
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Recently developed synthetic compounds González-Bello 19with piperacillin, ETX2514 (4 mg/mL) shows MIC values
of 4 and 2 mg/mL against OXA-24/40 and OXA-23 from A.
baumannii, respectively, while avibactam has poor in vitro
activity for both enzymes (MIC > 64 mg/mL). More
importantly, the combination of sulbactam/ETX2514
proved to have excellent in vitro activities of 0.5 mg/mL
for both enzymes. The resolution of the crystal structure
of OXA-24/40 from A. baumannii in complex with
ETX2514 (PDB entry 5VFD) revealed that the afore-
mentioned modifications in the avibactam scaffold
enhance apolar interactions with the tunnel-like entrance
and this explains the increase in activity. ETX2514 is now
in phase I clinical studies. Moreover, Papp-Wallace
et al. [20] showed that the replacement of the primary
amide group in C2 by other more complex amide groups,
specifically compounds WCK 5153, relebactam, zidebac-
tam (WCK 5107), or by a nitrile group (WCK 4234),
enhances the in vitro activity against OXA-24/40 and
OXA-23 from A. baumannii by up to 64-fold. In addition,
this enhancement is more pronounced in other OXA
enzymes such as KPC-2 or OXA-48, both from Klebsiella
pneumoniae.
Boronic acids
These compounds are mimics of the tetrahedral interme-
diate obtained after nucleophilic attack of the catalytic
serine of the b-lactamase enzyme to the b-lactam core of
the antibiotic (Figure 1b). Relevant examples are com-
pounds 79, which contain the thiophen-2-yl group of the
natural penicillins and a carboxylate moiety to interact
with the carboxylate binding pocket [21–26]. The reso-
lution of diverse crystal structures of the corresponding
enzyme adducts provides a good understanding of the
potency of these ligands. The use of fragment-based
design subnanomolar inhibitors led to the identification
of compounds 1012, which have good in vivo anti-
bacterial activity [27]. Acyclic boronic acids also proved
to be good inhibitors for both metallo-b-lactamases and
serine-b-lactamases [28,29]. The best example is
RPX7009, which is in phase 3 clinical trials [30].
Small molecules that target unexploited
objectives for bacterial survival
In general, the mode of action of antibiotics in clinical use
is based on the prevention of the synthesis and assembly
of key components for bacterial survival (bacterial viabil-
ity), the inhibition of cell wall biosynthesis, DNA repli-
cation, RNA transcription, the biosynthesis of folates or
the biosynthesis of proteins. Although this strategy is very
effective and has given rise to a good arsenal of life-saving
compounds, all of them inhibit a reduced number of
biological targets and resistance to them is well known
and widespread. It is not surprising, therefore, that there
is great interest in exploring other bacterial functions and
developing compounds with new mechanisms of action.
Two examples of pathways that have attracted significant
attention are highlighted below.www.sciencedirect.com Inhibitors of the lipid A biosynthesis
The enzymes of the lipid A pathway are attractive targets
for Gram-negative anti-infective drug discovery because
lipid A is: (i) the main component of the outer membrane
of the Gram-negative bacteria, which differentiate them-
selves from the Gram-positive ones; (ii) essential for
bacterial survival in relevant pathogens such as P. aeru-
ginosa or E. coli; and (iii) involved in the capacity of the
Gram-negative bacteria to cause infection. Among the
enzymes involved in the pathway, only the LpxC
enzyme, which catalyzes the second step of the route,
has been studied and several inhibitors are already in
clinical trials. The identification of the oxazoline hydro-
xamic acid L-573,655, followed by its improved version
L-161,240, a hydroxamic acid with the R configuration,
triggered all of the subsequent studies in this area [31].
L-161,240 is a reversible competitive inhibitor of the E.
coli enzyme with a Ki value of 24 mM and MIC values
against E. coli up to 1 mg/mL. As both L-573,655 and
L-161,240 are ineffective for P. aeruginosa treatments,
efforts were devoted to the development of novel chemi-
cal entities suitable for this pathogen. The most relevant
inhibitors reported are summarized in Figure 2 and they
all have a hydroxamic acid with the R configuration linked
to a long aliphatic tail that mimics the (R)-3-hydroxymyr-
istoate moiety of the natural substrate [32–41]. These
LpxC inhibitors have excellent in vitro activities against
both E. coli and P. aeruginosa. Among them, ACHN-475 is
already in clinical trials. The binding mode of these
inhibitors has been well established with the resolution
of a wide range of LpxC crystal structures from P.
aeruginosa, E. coli, Aquifex aeolicus and Yersinia enterocolitica
in complex with these compounds [42]. It is important to
highlight that the aforementioned inhibitors, and in gen-
eral the LpxC inhibitors, do not inhibit the growth of A.
baumannii (MIC > 512 mg/mL), another critical Gram-
negative pathogen reported by the WHO, since lipid A
is not essential for this bacterium [43].
Inhibitors of the shikimic acid pathway
The enzymes involved in the shikimic acid pathway have
attracted a great deal of attention for the development of
new anti-tubercular therapies since six of the seven
enzymes in the route are essential for Mycobacterium
tuberculosis – the causative agent of tuberculosis – and
they do not have any counterpart in human cells [44].
Four of the enzymes in the pathway are also essential for
Helicobacter pylori, the causative agent of gastric and
duodenal ulcers and also classified as a type I carcinogen,
and, therefore, inhibitors that disable these targets have
also been reported.
In accordance with the mechanism of action of the type II
dehydroquinase, which catalyzes the third step, a large
number of competitive reversible inhibitors have been
reported that mimic the enolate intermediate involved




E. coli  0.2 μg/mL E. coli  0.25  μg/mL 
P. aeruginosa 1.6  μg/mL    P. aeruginosa 1 μg/mL   
E. coli  0.125 μg/mL 
P. aeruginosa 0.25  μg/mL    
ACHN-975
LPC-009 G = H; 1R = H; 2R = Me (E.coli 0.05  μg/mL,  P.aeruginosa 0.74  μg/mL)    
LPC-011  G = NH2; 1R = H; 2R = Me (E.coli 0.03 μg/mL,  P.aeruginosa 0.5  μg/mL)    
LPC-058 G = NH2; 
1R = Me; 2R = CHF2 (E.coli 0.018 μg/mL,  P.aeruginosa 0.17  μg/mL)    
L-161,240
E. coli 1  μg/mL
L-573,655
Current Opinion in Pharmacology
(a)
(b)
Most relevant LpxC inhibitors. (a) First examples. (b) Most potent inhibitors reported. MIC values against E. coli and P. aeruginosa are also
included.order to achieve good affinity for this enzyme, since it is a
key point for recognition for all enzymes in the pathway,
obtaining good in vitro activities has been the bottleneck
for many of the developed inhibitors. Considering that
the low in vitro activity obtained could be due to the high
hydrophilicity of the compounds, lipophilic prodrugs
(ester prodrug form) were designed. In principle, these
ester derivatives would be slowly hydrolyzed to the
carboxylate active form after absorption by the bacterium
(cytosol). Fortunately, the in vitro activity dramatically
increases with the stability of the ester against hydrolysis,
proving to be the propyl ester derivatives the most effi-
cient ones. Compound 14 was the most active example,
with an MIC value of 5 mg/mL, and its active form
compound 13 gave a Ki of 28 nM (Figure 3) [45]. The
resolution of the crystal structures of the DHQ2
enzyme from H. pylori and M. tuberculosis in complex
with these types of compounds revealed that the aromatic
moiety freezes the substrate-covering loop, which con-
tains two essential residues, in an inactive conformation
for catalysis. Thus, this moiety interacts with the catalytic
tyrosine of the loop by p-stacking and expels the catalytic
arginine from the active site [45,46].
From a library of about 400 anti-mycobacterial com-
pounds previously identified by the NIH Tuberculosis
Antimicrobial Acquisition and Coordination FacilityCurrent Opinion in Pharmacology 2019, 48:17–23 (TAACF), Simithy et al. [47] identified an inhibitor of
shikimate kinase from M. tuberculosis, the fifth enzyme of
the pathway, namely the oxadiazole-amide 15, which had
an MIC value of 0.86 mg/mL and an IC50 value of 3.43 mM
with the isolated enzyme. Moreover, considering the
large conformational changes required for the shikimate
kinase enzyme in the LID and shikimic acid binding
domains for product release, diverse C5-substituted shi-
kimic acid analogs were developed to stabilize an inactive
open conformation of the enzyme [48]. The 3-nitrobenzyl
(16) and 5-benzothiophenyl (17) derivatives proved to be
the most potent inhibitors, with Ki values of 460 nM and
560 nM, respectively. Ethyl ester 18 (a proform of 17) was
the most efficient derivative in achieving good in vitro
activity against H. pylori and this had an MIC value of
4 mg/mL.
Zeneca Pharmaceuticals discovered that (6S)-6-fluoroshi-
kimic acid (19), a fluorinated analog of the natural sub-
strate of shikimate kinase, inhibited the growth of E. coli
B with an MIC value of 0.25 mg/mL [49]. The antibacte-
rial activity of 19 is due to the irreversible inhibition of
4-amino-4-deoxychorismate synthase by 2-fluorochoris-
mic acid (20) [50]. The latter compound is generated
in vivo from 19 by the last three enzymes of the pathway,
specifically shikimate kinase, EPSP synthase and chor-
ismate synthase.www.sciencedirect.com
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Figure 3
15 IC50 = 3.43 μM, MIC (H37Rv) = 0.86  μg/mL 13 G = H, Ki = 28 nM
14 G = n-Pr
MIC (H37Rv) = 5 μg/mL
16 Ki = 460 nM 17 G = H, Ki = 560  nM
18 G = Et, MIC (H.pylon) = 4 μg/mL 
19 MIC (E. coli B) = 0.25  μg/mL 
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Most relevant inhibitors of the shikimic acid pathway with antibacterial activity.Conclusions and outlook
After a prolonged and incomprehensible lethargy, the
future of the discovery of new anti-infective agents is
compelling. In the foreseeable future, combination therapy
strategies will probably be the most successful since (i) they
do not require the identification and validation of new
therapeutic targets; and (ii) they also allow us to preserve
and/or rescue drugs that have been in use for years but are
now less effective. This is perhaps why such compounds
are the most common in the still limited new treatments in
clinical studies. However, the development of compounds
with new mechanisms of action, despite the challenges and
the cost, can dramatically expand our ability to control
bacteria. This approach will provide new weapons to deal
with this significant problem.Therecent progress is already
very significant, as shown by the examples discussed here.
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44. González-Bello C: Inhibition of shikimate kinase and type II
dehydroquinase for antibiotic discovery: structure-basedwww.sciencedirect.com
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